Major clinical trials have failed to demonstrate the neuroprotective benefits of albumin observed in experimental studies and have instead shown that early albumin administration may increase the risk of adverse effects, including pulmonary edema and cerebral hemorrhage [24,25]. This evidence concerns the gene ALB and pulmonary edema.